Spark Therapeutics Reports Second Quarter 2018 Financial Results and Recent Business Progress
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/6/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- S&P Dow Jones Indices adds Bloom Energy to S&P 500 index
- Citi highlights best Gen AI stocks to own for 2027
- Dell’s earning report was bullish for Intel CPU demand, analyst says
- Netflix raises prices in Germany and Austria, Citi comments
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Spark Therapeutics (ONCE) PT Lowered to $61 at SunTrust Robinson Humphrey
August 7, 2018 3:32 PM EDTSunTrust Robinson Humphrey lowered its price target on Spark Therapeutics (NASDAQ: ONCE) to $61.00 (from $102.00) while maintaining a Buy rating.
Analsyt Edward Nash commented, "Updated data from hemophilia A program dims outlook as shares tumble 28% intraday (vs S&P50 up 0.3%). While the mean... More
Spark Therapeutics (ONCE) PT Lowered to $80 at Cowen
August 7, 2018 3:31 PM EDTCowen lowered its price target on Spark Therapeutics (NASDAQ: ONCE) to $80.00 (from $90.00) while maintaining a Outperform rating.
Analyst Phil Nadeau commented, "Spark reported Q2 financials and provided an update on the SPK-8011 clinical program. Five of seven patients treated with... More
Cantor Fitzgerald Defends Spark Therapeutics (ONCE), Saying They Didn't Expect Perfection
August 7, 2018 9:34 AM EDTCantor Fitzgerald analyst Elemer Piros came out to defended Spark Therapeutics (NASDAQ: ONCE) following data, saying while the market expected perfection, they didn't.
Piros commented, "We reiterate our Overweight rating and 12-month PT of $103 on Spark Therapeutics following 2Q18 financial results and program... More
BioMarin Pharma (BMRN) Climbs Following Hemophilia A Gene Therapy Data from Rival Spark Therapeutics (ONCE)
August 7, 2018 8:20 AM EDTBioMarin Pharma (NASDAQ: BMRN) Climbs Following Hemophilia A Gene Therapy Data from Rival Spark Therapeutics (NASDAQ: ONCE)
Spark Therapeutics (ONCE) Reports Q2 Loss Per Share of $2.07
August 7, 2018 7:35 AM EDT(Updated)
Spark Therapeutics (NASDAQ: ONCE) reported Q2 EPS of ($2.07), $1.97 worse than the analyst estimate of ($0.10). Revenue for the quarter came in at $25.2 million versus the consensus estimate of $29 million.
As of July 13, 2018, preliminary Phase 1/2 data for investigational SPK-8011 for hemophilia A... More
